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Abstract
Background: The continuous exposure of esophageal epithelium to refluxate may induce ectopic expression of
bile-responsive genes and contribute to the development of Barrett’s esophagus (BE) and esophageal
adenocarcinoma. In normal physiology of the gut and liver, the nuclear receptor Pregnane × Receptor (PXR) is an
important factor in the detoxification of xenobiotics and bile acid homeostasis. This study aimed to investigate the
expression and genetic variation of PXR in reflux esophagitis (RE), Barrett’s esophagus (BE) and esophageal
adenocarcinoma.
Methods: PXR mRNA levels and protein expression were determined in biopsies from patients with
adenocarcinoma, BE, or RE, and healthy controls. Esophageal cell lines were stimulated with lithocholic acid and
rifampicin. PXR polymorphisms 25385C/T, 7635A/G, and 8055C/T were genotyped in 249 BE patients, 233 RE
patients, and 201 controls matched for age and gender.
Results: PXR mRNA levels were significantly higher in adenocarcinoma tissue and columnar Barrett’s epithelium,
compared to squamous epithelium of these BE patients (P < 0.001), and RE patients (P = 0.003).
Immunohistochemical staining of PXR showed predominantly cytoplasmic expression in BE tissue, whereas nuclear
expression was found in adenocarcinoma tissue. In cell lines, stimulation with lithocholic acid did not increase PXR
mRNA levels, but did induce nuclear translocation of PXR protein. Genotyping of the PXR 7635A/G polymorphism
revealed that the G allele was significantly more prevalent in BE than in RE or controls (P = 0.037).
Conclusions: PXR expresses in BE and adenocarcinoma tissue, and showed nuclear localization in adenocarcinoma
tissue. Upon stimulation with lithocholic acid, PXR translocates to the nuclei of OE19 adenocarcinoma cells.
Together with the observed association of a PXR polymorphism and BE, this data implies that PXR may have a
function in prediction and treatment of esophageal disease.
Background
Persistent regurgitation of gastroduodenal contents into
the lower esophagus causes mucosal injury manifested
as reflux esophagitis (RE) [1,2]. As a complication of
chronic RE, a Barrett’s esophagus (BE) can develop [3,4].
BE is defined as an acquired condition in which the
stratified squamous epithelium of the lower esophagus
is replaced by specialized intestinal epithelium [5]. It is
the sole commonly recognized risk factor for the devel-
opment of esophageal adenocarcinoma (EAC) [6,7] and
has an increasing incidence in the Western world [8].
While the importance of acid and bile exposure in the
development of BE is well established [1,5,9,10], only a
small percentage of BE patients will ultimately develop
EAC. It remains largely unclear which factors control
the rate of neoplastic progression in BE [11]. A growing
body of evidence suggests that the intrinsic adaptive
response to the toxic bile acids from the gastroduodenal
contents is unable to prevent injury to the esophageal* Correspondence: A.vandewinkel@erasmusmc.nl1Department of Gastroenterology and Hepatology, Erasmus University
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lining, thus suggesting a role for bile-induced signalling
in the progression of BE [12].
An important step in understanding the adaptive
defence mechanism against toxic substances has been the
identification and characterization of the nuclear pregnane
× receptor (PXR) [13-16]. PXR belongs to the nuclear
receptor subfamily of ligand-activated transcription factors
that play a key role in the regulation of biliary transport
systems and enzymes that confer a protective role against
toxic bile acids [12]. This group of nuclear receptors
includes the constitutive androstrane receptor and the
vitamin D receptor [17,18]. In humans, PXR is most abun-
dantly found in the liver, the small intestine and the colon
[13,15,16,19]. It is activated by a structurally diverse array
of xenobiotics and endogenous compounds, including bile
acids and steroid hormones [13,17,18]. Variability at the
PXR genetic locus is therefore thought to be associated
with pathophysiological changes in steroid, cholesterol or
bile acid levels [14]. Polymorphisms in the PXR gene are
associated with diseases such as inflammatory bowel dis-
ease and primary sclerosing cholangitis [20,21]. As these
chronic inflammatory diseases are associated with aberrant
bile acid metabolism, there may also be a link between
PXR and BE.
The specific aim of this study was to explore the
expression and distribution of PXR in BE and adenocar-
cinoma patients and analyse possible associations in the
PXR gene with esophageal disease. We show that PXR
expresses in tissue of BE and adenocarcinoma patients,
and that it translocates to the nucleus in esophageal
adenocarcinoma cells upon bile acid stimulation. In
addition, a link between PXR polymorphisms and eso-
phageal disease was found.
Methods
Human specimens
For immunohistochemistry, multiple biopsies of adeno-
carcinoma tissue (n = 19), columnar epithelium from BE
patients without dysplsia (n = 28) and squamous epithe-
lium from RE patients (n = 8) were taken at the same
distance from the z-line. As healthy controls we
included subjects that had no gastroesophageal reflux
disease (GERD) symptoms or endoscopically detected
aberrations of the esophagus (n = 3). The number of
biopsies taken was approximately four per patient, and
varied between one and eight biopsies. For each patient,
all biopsy specimens were embedded in one single block
of paraffin and were therefore stained and analyzed in
one slide. Histologic diagnosis was made by two experi-
enced gastrointestinal pathologists (HD and HV). All
patients had specialized intestinal metaplasia and were
graded according to the most severe stage found. Cases
on which agreement could not be reached or that were
indefinite for dysplasia were excluded from this study.
Table 1 gives patient characteristics of the population
used for analysis of PXR mRNA levels. mRNA levels
were determined in a total of 119 esophageal samples,
counting biopsies from 11 adenocarcinoma patients,
duplicate biopsies of both the squamous and the colum-
nar epithelium from BE patients (n = 21), squamous
epithelium of RE patients (n = 7), and squamous epithe-
lium of healthy controls (n = 5) without GERD symp-
toms or endoscopically detected aberrations of the
esophagus. All BE patients had histologically confirmed
intestinal metaplasia without high-grade dysplasia.
Characteristics of the group included in this study for
genotyping are shown in Table 2. The total of 683
genetically unrelated Caucasians included 249 BE
patients, 233 RE patients and 201 controls without any
history of GERD symptoms, who all visited the endo-
scopy unit of the Erasmus MC-University Medical Cen-
ter Rotterdam or the IJsselland Hospital in Capelle aan
den IJssel between November 2002 and February 2005
[22]. This study was approved by the institutional ethics
review committees, and all patients gave informed con-
sent before participating in the study.
Cell lines
The human adenocarcinoma cell line OE19 and human
squamous epithelial cell line HET1A were obtained from
the ATCC. OE19 cells were grown in RPMI 1640 supple-
mented with 10% fetal calf serum (FCS), 2 mmol/l gluta-
mine, 100 units/ml penicilline and streptomycin. HET1A
cells were cultured in serum-free BRFF-EPM2 medium
supplemented with 100 units/ml penicilline and strepto-
mycin. Cells were maintained routinely at 37°C in 5%
CO2 humidified atmosphere. After a period of at least 24
h to allow cells to adhere they were stimulated with 10
μM of rifampicine, 50 μM lithocholic acid (LCA), or 50
or 100 μM taurolithocholic acid (TLCA) for 24 h.
Real-Time PCR mRNA quantification from human
esophagus samples
Total RNA was extracted from tissue biopsies using
TriReagent (Sigma, St Louis, MO) and purified using an
RNeasy micro column kit (Qiagen, Hilden, CA). One-
fortieth of a 1 μg cDNA synthesis reaction (iScript
Table 1 Patient characteristics for PXR mRNA analysis
RE
(n = 7)
BE
(n = 21)
EAC
(n = 11)
Age, y (range)* 43 (21-60) 61 (34-78) 62 (42-73)
Male, (%)* 71 71 82
Type of epithelium Sq Sq, CE tumor
RE: reflux esophagitis, BE: Barrett’s esophagus, EAC: esophageal
adenocarcinoma, Sq: squamous epithelium, CE: columnar epithelium
*Groups did not differ significantly in gender. As expected, BE and EAC
patients were somewhat older than RE patients
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cDNA Synthesis Kit; Bio-Rad) was used in a 25 μl Real
Time-PCR using SYBR GreenER (Invitrogen, Carlsbad,
CA). The following primers were used for PXR gene
amplification: 5’- ATGGCAGTGTCTGGAACTAC-3’
and 5’- CAGTTGACACAGCTCGAAAG-3’. Duplicate
samples were run three times in independent PCR runs
and the average level of PXR was normalized to
GAPDH using the ΔCt method [23].
Immunohistochemistry
Formalin fixed, paraffin embedded, five μm sections
were mouned on glass slides. After deparaffinization in
xylene and dehydration in alcohol, endogenous peroxi-
dase was inactivated by incubation with 1% hydrogen
peroxidase in methanol for 20 min. Microwave pretreat-
ment in glycin-HCl/EDTA buffer (50 mM Glycin, 10
mM EDTA, pH 3.5) was performed for 10 min. After
treatment with 10% normal human plasma/10% goat
serum to block non-specific antibody binding, sections
were incubated overnight at 4°C with a rabbit anti-
human PXR antibody (diluted 1:200, clone poly6169;
Biolegend; San Diego, USA), followed by a biotin-labeled
mouse anti-rabbit IgG (diluted 1:200; Dako, Glostrup,
Danmark), and streptavidin-horseradish peroxidase
(diluted 1:300, Dako) and visualized with diaminobenzi-
dine. Nonspecific background controls were done by
omitting the primary antibody and an isotype control
was included. Samples of the terminal ileum served as a
positive control. Sections were evaluated at a 200- and
400-fold magnification using light microscopy (Axioskop
20, Zeiss) by two independent observers (AW and KZ).
At least 100 cells were counted in representative areas
of longitudinally sectioned crypts in BE cases or high
power fields in adenocarcinoma cases. For quantification
only cases with nuclear protein expression were consid-
ered PXR positive, with cases evaluated as positive for
PXR when more than 2% of counted cells showed
nuclear positivity of PXR protein.
Confocal microscopy
Cells were cultured on coverslips washed with phos-
phate buffered saline (PBS) and fixed with 2% parafor-
maldehyde for 10 min. After washing, cells were
permeabilized with 0.2% Triton ×100 for 20 min and
then blocked with 5% goat serum and 5% normal
human plasma in PBS with 5% BSA. Cells were incu-
bated with mouse IgG or anti-hPXR antibody (1:200;
Biolegend, San Diego, USA) at 4°C overnight and then
probed with 1:200 dilution of goat anti-rabbit Alexafluor
594 (Invitrogen; Oregon, USA). Hoechst 33342 was used
to stain nuclei. Coverslips were mounted onto glass
slides with gelvatol and visualized under a Zeiss LSM
410 laser-scanning confocal microscope (Zeiss, Oberko-
chen, Germany).
Genotyping
Genomic DNA was extracted from 5 ml of whole blood by
a wizard genomic DNA purification kit (Promega, Madi-
son, USA). We analyzed polymorphisms -25385C/T,
7635A/G, and 8055C/T as these should be informative for
eight PXR polymorphisms and were observed by Zhang et
al [14] to have an effect on PXR function in humans.
Assay validation setup was performed by K-Biosciences
(Herts, UK) before performing a double blind analysis of
PXR SNPs with a competitive allele-specific PCR system
using primers designed in flanking region of the SNP
located at -25385; TGGTCATTTTTTGGCAATCC-
CAGGTT[C/T]TCTTTTCTAC CTGTTTGCTCAATCG
at 7635; AGGAGCCATCCTCCCTCTTCCTCTC[A/G]
CCCCCAA CTTCTGGATTATGGGATG and at 8055;
GCTTGCTGAGAAGCTGCCCCTCCAT[C/T]CT
GTTACCATCCACAGGTGGCTTCC of the PXR gene
NR1I2.
Statistical analyses
The study was powered (80%) to allow detection of a
10% difference in genotype distribution of the PXR poly-
morphisms between the groups by performing Chi-
square analysis. Odds ratio (OR) and 95% confidence
interval (95% CI) were calculated by risk estimate analy-
sis. All statistical analyses were conducted using SPSS
v11.0 (SPSS, Chicago, IL) and two-sided significance was
taken as P < 0.05.
Results
PXR gene expression is elevated in BE and
adenocarcinoma
PXR mRNA was determined by Real-Time PCR in a
group of 44 subjects with different esophageal patholo-
gies (Table 1). As shown in Figure 1A, levels of PXR
mRNA were found consistently higher in columnar tis-
sue compared to matching squamous tissue (P < 0.001),
in which levels of PXR transcripts were barely detect-
able. Figure 1B shows interindividual differences in PXR
expression between RE, squamous and columnar epithe-
lium of BE, and EAC. The levels of PXR mRNA in the
BE columnar epithelium were higher than in squamous
epithelium of RE (P = 0.003, Figure 1B) and healthy
controls (P = 0.002, data not shown). Also PXR gene
Table 2 Patient characteristics per group for genotyping
HC
(n = 201)
RE
(n = 233)
BE
(n = 249)
Age, y (range) 57 (18-90) 54 (19-88) 61 (33-95)
Male, (%) 57 54 69
Length of BE segment, cm (SD) NA 0 4.23 (2.39)
HC: healthy controls, RE: reflux esophagitis, BE: Barrett’s esophagus, NA: not
applicable
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expression in tissue of adenocarcinoma patients was sig-
nificantly higher than in squamous samples from BE
patients and healthy controls. Comparing RE with con-
trols, only one patient showed a strong increase in PXR
mRNA and thus overall difference in mRNA levels
between these two groups did not reach statistic signifi-
cance (Figure 1B).
PXR protein distribution in BE and adenocarcinoma tissue
To test if the presence of PXR mRNA corresponded
with the expression of PXR protein, esophageal biopsies
of 39 patients were stained for PXR by immunohisto-
chemistry. Figure 2 depicts representative stainings of
PXR on esophageal biopsy specimens of healthy con-
trols, and RE, BE, and adenocarcinoma patients. None
Figure 1 Relative mRNA levels of PXR in esophageal epithelium as determined by quantitative Real-Time PCR. (A) PXR levels in
columnar epithelium (CE) are normalized to adjacent squamous epithelium (Sq) using 2(-ΔΔCt) method [23] and are plotted for each of 21
Barrett’s esophagus (BE) patients. Error bars express a range which is a result of incorporating the standard deviation into the calculation. The
mean of this population renders a strong significant increase of PXR mRNA levels in CE compared to Sq of BE patients (P < 0.001). (B) PXR
mRNA levels are calculated using 2(-ΔCt) to show interindividual differences in PXR expression in RE, BE, and EAC patients and plotted on a log
scale. Levels in Sq from patients with reflux esophagitis, and patients with BE are lower than in CE derived from the esophagus of BE patients (P
= 0.003 and P < 0.001 respectively). mRNA levels in tissue from adenocarcinoma patients did not differ statistically from CE of BE patients, but
was significantly higher than all Sq tissues. The detection limit for this assay was 0.0001.
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of the normal squamous esophageal samples (n = 3)
stained positive for PXR (Figure 2A). Also, no specific
PXR signal was detected in RE samples (Figure 2B). In
patients with histologically confirmed BE (n = 28), six
cases of nuclear positivity were found (Figure 2C). In
17/19 adenocarcinoma patients, PXR expression was
observed in the nuclei of cancer cells (Figure 2D). This
was significantly higher compared to nuclear PXR
expression in BE tissue (P < 0.01, Figure 2E).
Exposure to bile acids does not affect PXR mRNA levels,
but does induce nuclear translocation
PXR mRNA levels were analyzed in HET1A and OE19
cells upon stimulation with 50 or 100 μM TLCA. PXR
levels in the OE19 adenocarcinoma cell line were higher
than in the squamous epithelial HET1A cells (P = 0.02),
but mRNA levels did not differ between unstimulated
cells and cells stimulated with TLCA (Figure 3A). Figure
3B shows immunofluorescence of PXR in the nuclei of
OE19 cells that were unstimulated, or stimulated with
TLCA. Induction with rifampicine was taken as a posi-
tive control. More nuclear PXR staining was observed in
cells stimulated with 10 μM rifampicine (data not
shown) and 50 μM TLCA compared to unstimulated
cells, with most intense staining observed in TLCA sti-
mulated OE19 cells. In summary, exposure of adenocar-
cinoma cells to bile acids and xenobiotics appears to
induce nuclear translocation of PXR independent of its
gene levels.
PXR polymorphism 7635AG is associated with BE
Polymorphisms at location 7635 and 8055 of the PXR
gene have previously been found to be located in differ-
ent linkage disequillibrium blocks and are thought to
have an effect on PXR activity [14]. In our cohort the
PXR gene polymorphisms were in Hardy-Weinberg
Equilibrium. No significant association of SNP -25385C/
T with BE or RE was found (P > 0.5; data not shown).
Figure 2 Result of PXR immunohistochemical staining on
esophageal biopsy specimens. (A) Esophagus of healthy controls
is lined by a stratified squamous epithelium and is negative for PXR
(200×). (B) The esophageal mucosa of patients with reflux
esophagitis is damaged and inflamed and demonstrates a weak
signal for PXR (brown) in the cytoplasm of epithelium (200×). (C)
Barrett’s epithelium is characterized by a single layer of columnar
epithelium with the presence of typical goblet cells. Cytoplasmic as
well as some nuclear PXR expression is observed (400×). (D) Cells of
adenoma tissue show high levels of nuclear PXR expression (400×).
(E) Quantification showed that the percentage of cases with more
than 2% PXR-positive nuclei was significantly higher in EAC than in
BE (P < 0.01).
Figure 3 PXR mRNA levels and nuclear translocation of PXR
protein in esophageal cell lines stimulated with bile acids. (A)
PXR mRNA levels are significantly higher in OE19 than in HET1A (P
= 0.02). Bile stimulation with 50 μM or 100 μM of TLCA did not
affect PXR mRNA levels compared to unstimulated conditions. (B)
After immunofluorescent staining of PXR (red) and nuclei (green),
localization in OE19 cells was visualized by a confocal laser
microscope (1000×). In unstimulated cells, PXR was predominantly
found in the cytoplasm. Upon 24 h of stimulation with 50 μM of
TLCA, PXR translocation from the cytoplasm to the nuclei was
observed.
van de Winkel et al. BMC Gastroenterology 2011, 11:108
http://www.biomedcentral.com/1471-230X/11/108
Page 5 of 9
Allele frequencies of SNP 7635A/G and 8055C/T for
patient and healthy control populations are listed in
Table 3. Minor allele frequencies of these SNPs were in
consensus with previous observations in European con-
trol cohorts [14,24,25]. Subjects carrying the SNP 7635G
allele had an increased risk of BE (OR 1.36, 95% CI
1.03-1.79). In comparing genotype distributions, an
increase was demonstrated in the minor allele frequency
among BE patients as compared with RE patients and
healthy controls for both 7635A/G and 8055C/T. For
SNP 7635A/G this trend was statistically significant (P =
0.037, Figure 4).
Discussion
The precise pathophysiological mechanisms causing BE
is still unclear, but the combination of gastric acid and
bile acids from the gastroduodenal reflux is commonly
acknowledged as the key factor in the development of
BE [26]. At low pH, bile acids are thought to cause eso-
phageal mucosal injury, which has been substantiated
both in vitro and in animal model systems [27-29].
The NR1I family of orphan nuclear receptors are
known to prevent toxic accumulations of xenobiotics
within cells by regulating a broad range of cellular trans-
porters [17,30,31]. The nuclear receptor PXR is a mem-
ber of this family and functions in the enterohepatic
organs as a detoxifier and regulator of bile acid homeos-
tasis [12-16]. It can bind a variety of bile acids [32,33]
and subsequently regulate the expression of a multitude
proteins that transport bile acids across cell membranes
[34-36]. These include the multidrug resistance (MDR)1
gene [37,38], which encodes the efflux protein P-glyco-
protein that removes xenobiotics from cells [39]. Other
bile acid transporters that are induced by PXR include
the multidrug resistance associated protein (MRP)2 and
3 [40-42] and the organic anion transporting polypep-
tide (OATP)1 and 2 [42-44]. From studies in mice it
was concluded that the function of PXR is of particular
importance when bile acid concentrations reach patho-
physiologic levels [33,45].
PXR expression is known in healthy liver and intest-
inal tract, but in cancer it has yet to be explored. There-
fore, in this study we investigated the expression and
significance of PXR in esophageal pathology. We did
not detect PXR in normal squamous epithelium or in
the squamous epithelium of RE patients. PXR did how-
ever express at both mRNA and protein level in colum-
nar epithelium, and was significantly lower in adjacent
squamous esophageal epithelium of the same patient. In
samples from adenocarcinoma patients PXR was clearly
observed the nucleus. PXR mRNA levels between BE
and EAC do not differ, but nuclear PXR protein expres-
sion does increase in EAC. Perhaps, this is an effect of
difference posttranscriptional modifications between the
stages. It could also indicate a translocation from the
cytoplasm to the nucleus occuring during progression
from BE to EAC, as our studies showed translocation
from cytoplasm to the nuclei of adenocarcinoma cells in
vitro after stimulation with rifampicine or litholic acid.
These processes and their significance to PXR function
need to be further explored, and a first step in this
could be Western blot analysis on subcellular fractions
of BE and EAC cells.
Previous studies have suggested that PXR expression
in cancer cells can interfere with the metabolism and
responsiveness to chemotherapeutics, such as irinotecon
and tamoxifen [46,47]. They suggest this drug resistance
involves the metabolizing enzyme CYP3A4, one of the
key target genes of PXR [15]. These effects on the meta-
bolism of anticancer agents are especially important
considering that PXR ligands include endogenous ster-
oids and bile acids, as well as numerous environmental
chemicals and dietary constituents. It has yet to be
investigated whether higher levels of PXR in the esopha-
gus also affects responsiveness to chemotherapy.
Given the relatively low rare allele frequency for SNP
8055C/T, our population size may have been insufficient
to detect a statistically significant association. Validation
of our findings will require a well-characterized popula-
tion from a multicenter study. Recent studies associate
PXR polymorphisms with other pathogenic conditions
of the gastrointestinal tract, such as inflammatory bowel
disease [20] and primary sclerosing cholangitis [21].
Since associations with the two PXR SNPs in this study
are in line with previous findings in IBD [20], this draws
attention on a possible link of the functional effect of
these SNPs with chronic inflammation. It is well known
that inflammation, through the activation of NF-B
pathway leads to a decrease of CAR, PXR and RXR-
alpha expression and the expression of their target
Table 3 Allele frequencies of PXR SNPs at locus 7635 and 8055
SNP Allele frequency, no. (fraction) HC vs RE HC vs BE
locus Allele HC RE BE OR (95% CI) OR (95% CI)
7635 A
G
267 (0.674)
129 (0.326)
294 (0.636)
168 (0.364)
298 (0.603)
196 (0.397)
1.18 (0.89-1.57) 1.36 (1.03-1.79)
8055 C
T
321 (0.863) 51 (0.137) 381 (0.832)
77 (0.168)
397 (0.814)
91 (0.186)
1.27 (0.87-1.87) 1.44 (0.99-2.10)
HC: healthy controls, RE: reflux esophagitis, BE: Barrett’s esophagus
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genes. In addition, it has recently been shown that the
mutual repression between PXR and NF-B signalling
pathways provides a molecular mechanism linking xeno-
biotic metabolism and inflammation [48].
Although it cannot be ruled out that the observed link
between BE and PXR levels is not the cause but only
the consequence of the metaplasia from squamous to
intestinal-type mucosa, the link with PXR-activity asso-
ciated SNPs suggest a active role of PXR in BE patho-
physiology. Further research should focus on the
biologic function of PXR in BE and EAC, especially
because PXR protein expression was observed in only
few nuclei in Barrett’s epithelium whereas EAC tissue
was abundant with PXR positive nuclei. Here, we chose
LCA to study nuclear translocation as it is the endogen-
ous ligand with the highest binding affinity for PXR. As
supraphysiological levels of LCA were used to stimulate
esophageal cells, further research will be required using
extensive stimulation assays that mimick the in vivo
situation by long-term repetitive stimulations with a mix
of bile acids in physiologic concentrations as recently
performed [49]. For a complex disease such as BE,
development and validation of representative animal
models will be of great value to investigate whether PXR
plays a protective role in the development of BE or if it
has a detrimental effect on neoplastic progression.
Conclusions
In summary, PXR which is normally not present in the
squamous esophageal epithelium, is expressed highly in
the columnar esophageal epithelium of BE patients and
tumor tissue of EAC patients. At a protein level, this
expression appears to be more nuclear in EAC than in
BE. Upon stimulation with lithocholic acid, PXR translo-
cates to the nuclei of OE19 adenocarcinoma cells.
Together with the observed association of a PXR-activity
associated SNPs and BE, this data implies that PXR may
have a function in predicting progression and treatment
of esophageal disease, though further studies are war-
ranted to support this hypothesis.
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